Eitan Kugler, MD PhD

Peer-Reviewed Articles

1. Bazinet, A, Bataller Torralba, A, Chien, KS, Sasaki, K, Montalban Bravo, G, Hammond, DE, Bouligny, IM, Swaminathan, M, Jen, WY, Kugler, E, Kanagal Shamanna, R, Kadia, TM, Borthakur, G, DiNardo, C, Short, NJ, Pemmaraju, N, Jabbour, EJ, Daver, N, Ravandi-Kashani, F, Urrutia, S, Gener-Ricos, G, Braish, J, Briski, RE, Rodriguez-Sevilla, JJ, Li, Z, Champlin, RE, Shpall, E, Alousi, AM, Oran, B, Hosing, C, Ramdial, JL, Olson, AL, Pierce, S, Chen, J, Kantarjian, HM, Garcia-Manero, G, Popat, UR. Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes. Blood cancer journal 16(1), 2026. e-Pub 2026. PMID: 41896225.
2. Jen WY, Jabbour E, Kugler E, Jain N, Garris R, Short NJ, Pierce S, Khouri I, Wang SA, Haddad F, Ravandi F, Kantarjian H. Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 26(8):519-525, 2026. e-Pub 2026. PMID: 42392945.
3. Kantarjian H, Jen WY, Kugler E, Garris R, Pierce S, Jain N, Short NJ, Khouri I, Loghavi S, Haddad FG, Ravandi F, Jabbour E. Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 132(15):e70533, 2026. e-Pub 2026. PMID: 42482409.
4. Kugler E, Ravandi F, Bazinet A, Dinardo CD, Daver N, Yilmaz M, Short NJ, Jen WY, Senapati J, Maiti A, Borthakur G, Garcia-Manero G, Kantarjian HM, Kadia TM. Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission. Haematologica, 2026. e-Pub 2026. PMID: 42489069.
5. Azevedo RS, Jabbour E, Jain N, Haddad FG, Kebriaei P, Khouri I, Shpall EJ, Champlin R, Karrar O, Maroun M, Senapati J, Kugler E, Garris RS, Ravandi F, Kantarjian H, Short NJ. Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage. Leukemia, 2026. e-Pub 2026. PMID: 42463941.
6. Jamison T, Jabbour E, Karrar O, Jain N, Haddad FG, Kebriaei P, Khouri I, Popat U, Yang H, Kugler E, Garris R, Garcia-Manero G, Kantarjian H, Short NJ. Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoring. Leuk Lymphoma:1-4, 2026. e-Pub 2026. PMID: 42220306.
7. Marvin-Peek J, DiNardo CD, Loghavi S, Ravandi F, Borthakur G, Daver NG, Kadia TM, Jabbour E, Dunbar A, Tang G, Short NJ, Haddad FG, Abbas HA, Kugler E, Maiti A, Issa GC, Takahashi K, Bhalla K, Pemmaraju N, Alvarado Y, Shpall EJ, Popat U, Ramdial J, Champlin RE, Kantarjian HM, Garcia-Manero G, Senapati J. Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy. Cancer 132(10):e70434, 2026. e-Pub 2026. PMID: 42089434.
8. Kantarjian, HM, Qiao, W, Jain, N, Jen, WY, Kugler, E, Short, NJ, Garris, R, Pierce, S, Kebriaei, P, Wang, SA, Haddad, FG, Ravandi-Kashani, F, Huang, X, Jabbour, EJ. Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia. Cancer 132(8), 2026. e-Pub 2026. PMID: 41954167.
9. Short, NJ, Jabbour, EJ, Macaron, W, Jain, N, Haddad, FG, Loghavi, S, Kadia, TM, Kebriaei, P, Kugler, E, Matthews, JA, Garris, R, Ravandi-Kashani, F, Kantarjian, HM. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 41120271.
10. Jen WY, Tang G, Kugler E, Croden J, Sasaki K, Bazinet A, Bataller A, Montalban-Bravo G, Borthakur G, Toruner GA, Loghavi S, Short NJ, Issa GC, Bouligny IM, Pierce S, Popat U, Pemmaraju N, Jabbour E, Garcia-Manero G, Bhalla K, Ravandi F, Daver NG, DiNardo CD, Kantarjian HM, Kadia TM. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. Br J Haematol 207(6):2451-2461, 2025. e-Pub 2025. PMID: 40983567.
11. Kugler E, Dasdemir E, Bataller A, Wang B, DiNardo CD, Daver N, Yilmaz M, Short NJ, Borthakur G, Kadia TM, Sasaki K, Hammond D, Bazinet A, Irajizad E, Thakral B, Pierce S, Reville P, Ravandi F, Abbas HA. Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions. Leuk Lymphoma:1-13, 2025. e-Pub 2025. PMID: 40164144.
12. Kugler, E, Kantarjian, H, Jabbour, EJ, Khaire, N, Short, NJ, Kadia, TM, Haddad, FG, Sasaki, K, Kanagal Shamanna, R, Garris, R, Ravandi-Kashani, F, Jain, N. Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 131(5), 2025. e-Pub 2025. PMID: 39980368.
13. Braish JS, Kugler E, Jabbour E, Woodman K, Ravandi F, Nicholas S, Jain N, Kantarjian H, Sasaki K. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(11):783-788, 2024. e-Pub 2024. PMID: 39013740.
14. Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, Canaani J, Moshe Y, Krayem B, Aumann S, Henig I, Vainstein V, Shargian L, Ganzel C, Yeshurun M, Levi I, Raanani P, Akria L, Ofran Y, Shimony S, Wolach O. Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia. Br J Haematol 205(3):932-941, 2024. e-Pub 2024. PMID: 38782575.
15. Strachan C, Kugler E, Devgan K, Nestor J, Afridi F, Raju R, Hunter K, Ahmed R. Intravenous iron infusions in pediatric patients: A retrospective review of efficacy and safety. J Investig Med 72(5):457-464, 2024. e-Pub 2024. PMID: 38429647.
16. Kugler E, Madiwale S, Yong D, Thoms JAI, Birger Y, Sykes DB, Schmoellerl J, Drakul A, Priebe V, Yassin M, Aqaqe N, Rein A, Fishman H, Geron I, Chen CW, Raught B, Liu Q, Ogana H, Liedke E, Bourquin JP, Zuber J, Milyavsky M, Pimanda J, Prive GG, Izraeli S. The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG. Nature communications 14(1):5871, 2023. e-Pub 2023. PMID: 37735473.
17. Rein A, Geron I, Kugler E, Fishman H, Gottlieb E, Abramovich I, Giladi A, Amit I, Mulet-Lazaro R, Delwel R, Groschel S, Levin-Zaidman S, Dezorella N, Holdengreber V, Rao TN, Yacobovich J, Steinberg-Shemer O, Huang QH, Tan Y, Chen SJ, Izraeli S, Birger Y. Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency. Haematologica 108(9):2316-2330, 2023. e-Pub 2023. PMID: 36475518.
18. Goldberg I, Cohen E, Gafter-Gvili A, Shochat T, Kugler E, Margalit I, Goldberg E, Raanani P, Krause I. A Longitudinal Assessment of the Natural Change in Haemoglobin, Haematocrit, and Mean Corpuscular Volume with Age. Acta haematologica 146(3):206-213, 2023. e-Pub 2023. PMID: 36724761.
19. Kugler, E, Madiwale, S, Yong, D, Birger, Y, Thoms, JA, Sykes, DB, Yassin, M, Aqaqe, N, Rein, A, Fishman, H, Geron, I, Chen, CW, Raught, B, Liu, Q, Milyavsky, M, Pimanda, JE, Privé, GG, Izraeli, S. AML-131 ERG. Clinical Lymphoma, Myeloma and Leukemia 22:S215-S216, 2022. e-Pub 2022.
20. Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Ann Hematol 101(9):2001-2010, 2022. e-Pub 2022. PMID: 35739428.
21. Fishman H, Madiwale S, Geron I, Bari V, Van Loocke W, Kirschenbaum Y, Ganmore I, Kugler E, Rein-Gil A, Friedlander G, Schiby G, Birger Y, Strehl S, Soulier J, Knoechel B, Ferrando A, Noy-Lotan S, Nagler A, Mulloy JC, Van Vlierberghe P, Izraeli S. ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. Blood 139(3):399-412, 2022. e-Pub 2022. PMID: 34624096.
22. Mizrahi N, Kugler E, Hayman L, Yeshurun M, Grossman A, Raanani P, Wolach O. T-Lymphoblastic Leukemia/Lymphoma and Thymoma: A Case Report and Review of the Literature of a Rare Association. Acta Haematol 145(1):106-111, 2022. e-Pub 2022. PMID: 34537764.
23. Ling T, Birger Y, Stankiewicz MJ, Ben-Haim N, Kalisky T, Rein A, Kugler E, Chen W, Fu C, Zhang K, Patel H, Sikora JW, Goo YA, Kelleher N, Zou L, Izraeli S, Crispino JD. Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis. Blood 134(19):1619-1631, 2019. e-Pub 2019. PMID: 31409672.
24. Aqaqe N, Yassin M, Yassin AA, Ershaid N, Katz-Even C, Zipin-Roitman A, Kugler E, Lechman ER, Gan OI, Mitchell A, Dick JE, Izraeli S, Milyavsky M. An ERG Enhancer-Based Reporter Identifies Leukemia Cells with Elevated Leukemogenic Potential Driven by ERG-USP9X Feed-Forward Regulation. Cancer Res 79(15):3862-3876, 2019. e-Pub 2019. PMID: 31175119.
25. Yassin M, Aqaqe N, Yassin AA, van Galen P, Kugler E, Bernstein BE, Koren-Michowitz M, Canaani J, Nagler A, Lechman ER, Dick JE, Wienholds E, Izraeli S, Milyavsky M. A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity. Leukemia 33(8):2061-2077, 2019. e-Pub 2019. PMID: 30705411.
26. Kugler E, Cohen E, Goldberg E, Nardi Y, Levi A, Krause I, Garty M, Krause I. C reactive protein and long-term risk for chronic kidney disease: a historical prospective study. J Nephrol 28(3):321-7, 2015. e-Pub 2015. PMID: 24981713.
27. Kugler E, Levi A, Goldberg E, Zaig E, Raanani P, Paul M. The association of central venous catheter placement timing with infection rates in patients with acute leukemia. Leuk Res 39(3):311-3, 2015. e-Pub 2015. PMID: 25636357.
28. Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L, Lahav M, Yeshurun M, Shpilberg O, Herscovici C, Wolach O, Itchaki G, Bar-Natan M, Vidal L, Gafter-Gvili A, Raanani P. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. Am J Hematol 89(3):243-8, 2014. e-Pub 2014. PMID: 24178750.
29. Mouallem M, Zemer-Wassercug N, Kugler E, Sahar N, Shapira-Frommer R, Schiby G. Tumor lysis syndrome and malignant melanoma. Med Oncol 30(3):364, 2013. e-Pub 2013. PMID: 23673985.
30. Kugler E, Shoham-Vardi I, Burstien E, Mazor M, Hershkovitz R. The safety of a trial of labor after cesarean section in a grandmultiparous population. Arch Gynecol Obstet 277(4):339-44, 2008. e-Pub 2008. PMID: 17957377.

Other Articles

1. Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis. Annals of Hematology 101(9):2011, 2022. PMID: 35869985.

Editorials

1. Kugler E. Charting a path through resistance: histone deacetylase inhibitors for TP53-mutated B-cell acute lymphoblastic leukemia. Haematologica 109(6):1643-1645, 2024. PMID: 38356461.

Abstracts

1. Kugler E, Senapati J, Loghavi S, Ravandi F, Bazinet A, Bataller A, DiNardo C, Hammond D, Chien K, Jen W, Montalban-Bravo G, Sasaki K, Borthakur G, Kantarjian H, Garcia-Manero G, Kadia T. Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia. ASH, 2025. e-Pub 2025.
2. Azevedo RS, Kantarjian HM, Lavu S, Loghavi S, Jain N, Haddad F, Senapati J, Kugler E, Garris R, Takahashi K, Ravandi-Kashani F, Jabbour E, Short NJ. Impact of TP53 mutations and variant allelic frequency on survival in adults with newly diagnosed acute lymphoblastic leukemia. American Society of Clinical Oncology, 2025. e-Pub 2025.
3. Bazinet A, Garcia-Manero G, Bataller A, Urrutia S, Kadia TM, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Hammond D, Swaminathan M, Jen WY, Gener-Ricos G, Bouligny IM, Braish J, Kugler E, Champlin RE, Shpall EJ, Kantarjian HM, Popat UR. Allogeneic stem cell transplantation-related outcomes in myelodysplastic syndromes. American Society of Clinical Oncology, 2025. e-Pub 2025.
4. Marvin-Peek J, DiNardo C, Loghavi S, Ravandi F, Borthakur G, Daver N, Kadia T, Jabbour E, Dunbar A, Tang G, Short N, Haddad F, Jabbour J, Kugler E, Maiti A, Issa G, Takahashi K, Bhalla K, Pemmaraju N, Valero YA, Sasaki K, Shpall E, Popat U, Ramdial J, Champlin R, Garcia-Manero G, Kantarjian H, Senapati J. ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT). ASH, 2025. e-Pub 2025.
5. Senapati J, Jabbour E, Jain N, Chien K, Yilmaz M, Haddad F, Montalban-Bravo G, Kugler E, Jen W, Khouri R, Ohanian M, Garris R, Zhao M, Garcia-Manero G, Short N, Kantarjian H. Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial. ASH, 2025. e-Pub 2025.
6. Azevedo RS, Jabbour E, Jain N, Haddad F, Kebriaei P, Khouri I, Shpall E, Champlin R, Senapati J, Kugler E, Karrar O, Maroun E, Garris R, Ravandi F, Kantarjian H, Short N. Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia. ASH, 2025. e-Pub 2025.
7. Bouligny I, Chien K, Montalban-Bravo G, Bazinet A, Bataller A, Swaminathan M, Hammond D, Jen W, Kugler E, Jabbour E, Valero YA, Daver N, Kadia T, Andreeff M, Borthakur G, Jain N, Pemmaraju N, Ravandi F, Masarova L, Short N, Takahashi K, Yilmaz M, DiNardo C, Kanagal-Shamanna R, Mirabella B, Garcia-Manero G. A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes. ASH, 2025. e-Pub 2025.
8. Jamison T, Jabbour E, Jain N, Karrar O, Haddad F, Kebriaei P, Khouri I, Popat U, Yang H, Senapati J, Kugler E, Garris R, Garcia-Manero G, Kantarjian H, Short N. Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring. ASH, 2025. e-Pub 2025.
9. Kugler E, Furudate K, Ravandi F, Jain N, Borthakur G, Short N, Garris R, Kantarjian H, Jabbour E, Takahashi K. A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL. ASH, 2025. e-Pub 2025.
10. Bazinet A, Garcia-Manero G, Bataller A, Montalban-Bravo G, Sasaki K, Chien K, Hammond D, Bouligny I, Swaminathan M, Jen W, Kugler E, Kadia T, DiNardo C, Ravandi F, Kanagal-Shamanna R, Gener-Ricos G, Braish J, Urrutia S, Briski R, Rodriguez Sevilla JJ, Chen J, Pierce S, Oran B, Hosing C, Ramdial J, Alousi A, Olson A, Shpall E, Champlin R, Kantarjian H, Popat U. Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes. ASH, 2025. e-Pub 2025.
11. Bazinet A, Montalban-Bravo G, Bataller A, Chien K, Hammond D, Sasaki K, Bouligny I, Swaminathan M, Jen W, Kugler E, Loghavi S, Kanagal-Shamanna R, Pierce S, Chen J, Kadia T, DiNardo C, Borthakur G, Daver N, Jabbour E, Ravandi F, Oran B, Hosing C, Ramdial J, Alousi A, Olson A, Shpall E, Champlin R, Kantarjian H, Garcia-Manero G, Popat U. Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center. ASH, 2025. e-Pub 2025.
12. Kugler E, Dasdemir E, Wang B, Bataller A, Dinardo CD, Daver NG, Yilmaz M, Short NJ, Kadia TM, Sasaki K, Bazinet A, Pierce S, Reville PK, Ravandi-Kashani F, Abbas H. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions. American Society of Clinical Oncology, 2024. e-Pub 2024.
13. Kugler E, Desdemir E, Wang B, Bataller TA, DiNardo CD, Daver N, Yilmaz M, Short N, Kadia T, Sasaki K, Bazinet A, Pierce S, Reville P, Ravandi F, Abbas HA. Mutation patterns and Prognostic implications in Acute Myeloid Leukemia with chromosomal 7 deletions. EHA Annual Meeting, 2024. e-Pub 2024.
14. Shapiro AG, Winter E, Moshe Y, Katzenelenbogen Y, Jaitin D, Zada M, Barboy O, Yofe I, Chalan P, Phan ST, Giladi A, Shapiro M, Robinson R, Kugler E, Wolach O, Avivi Mazza I, Amit I. Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics. ASH Annual Meeting 142(Supp 1):599, 2023. e-Pub 2023.
15. Ram R, Amit O, Winer S, Moshe Y, Raanani P, Kugler E, Yeshurun M, Avivi I, Wolach O. Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis. ASH Annual Meeting 140(Supp 1):10637–10638, 2022. e-Pub 2022.
16. Kugler E, Shimony S, Canaani J, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O. Gilteritinib Monotherapy for Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia: A Real-World, Multi-Center, Matched Analysis. EHA Annual Meeting 6(S3):477-478, 2022. e-Pub 2022.
17. Kugler E, Madiwale S, Yong D, Birger Y, Thoms JA, Skyes DB, Yassin M, Aqaqe N, Rein A, Fishman H, Geron I, Chen C, Raught B, Liu Q, Milyavsky M, Pimanda J, Prive GG, Izraeli S. A single amino acid at PNT domain of ERG mediates its leukemogenic activity through interaction with the NCoR-HDAC3 co-repressor complex. EHA Annual Meeting 6(S3):622-623, 2022. e-Pub 2022.
18. Kugler E, Birger Y, Yong D, Thoms J, Rein A, Madiwale S, Pimanda J, Prive G, Izraeli S. The PNT Domain of ERG Regulates Hematopoietic Stemness and is Required for the Maintenance of ERG-Induced Leukemia. EHA Annual Meeting 2020 20(Supp 1):S180-S181, 2020. e-Pub 2020.
19. Kugler E, Birger Y, Darren Y, Thoms J, Rein A, Madiwale S, Pimanda J, Prive G, Izraeli S. ERG: from a fortuitous discovery to potential treatment for AML. SOHO.
20. Kugler E, Khaire NS, Jabbour E, Short Nj, Kadia TM, Haddad FG, Sasaki K, Kanagal-Shamanna R, Garris R, Ravandi F, Kantarjian HM, Jain N. Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant. ASH Annual Meeting.
21. Kugler E, Kantarjian HM, Bazinet A, Jen WY, Daver N, DiNardo CD, Short N, Senapati J, Borthakur G, Pemmaraju N, Issa G, Bataller A, Reville P, Garci G-Manero, Ravandi F, Kadia TM. Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission. ASH Annual Meeting.
22. Kugler E, Loghavi S, Ravandi F, DiNardo CD, Daver N, Kadia TM, Borthakur G, Issa G, Abbas H, Bose P, Senapati J, Kantarjian HM, Short N. Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis. ASH Annual Meeting.
23. Azevedo RS, Kantarjian H, Senapati J, Bouligny I, Bazinet A, Jen W, Alousi A, Popat U, Shpall E, Pemmaraju N, Jain N, Kugler E, Belgarde C, Jabbour E, Garcia-Manero G, DiNardo C, Daver N, Ravandi F, Kadia T. Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation. ASH.
24. Kugler E, Cohen E, Goldberg E, Nardi Y, Garty M, Krause I. C-Reactive protein and the long-term risk for decreased kidney function. European Congress of Internal Medicine.
25. Kugler E, Birger Y, Izraeli S. The role of the PNT domain in ERG leukemogenic pathway. Graduate student conference in genetics, genomics and evolution.
26. Kugler E, Birger Y, Izraeli S. The role of the PNT domain in ERG leukemogenic pathway. Graduate student conference in genetics, genomics and evolution.
27. Kugler E, Birger Y, Yong D, Rein A, Prive G, Izraeli S. Characterization of the pointed domain role in the transcription factor ERG leukemogenic pathway. The 9th German Israeli Cancer Research School on cancer stem cells and tumor heterogeneity, a scientific collaboration between the Israeli ministry of science and the German DKFZ.
28. Rein A, Birger Y, Kugler E, Huang Q, Chen SJ, Izraeli S. Creation and analysis of two mouse models revealing the role of Gata2 as a tumor suppressor. IUBMB focused meeting on GATA transcription factors.
29. Kugler E, Birger Y, Darren Y, Thoms J, Rein A, Madiwale S, Pimanda J, Prive G, Izraeli S. The PNT Domain of ERG Regulates Hematopoietic Stemness and is Required for the Maintenance of ERG-Induced Leukemia. SOHO.
30. Kugler E, Madiwale S, Birger Y, Darren Y, Thoms J, Sykes, D. B, Rein A, Pimanda J, Prive G, Izraeli S. ERG - from a fortuitous discovery to potential treatment in AML. The Israel society of hematology and transfusion medicine meeting.
31. Kugler E, Madiwale S, Birger Y, Darren Y, Thoms J, Sykes, D. B, Rein A, Pimanda J, Prive G, Izraeli S. The NCOR-HDAC3 co-repression complex modulates the leukemogenic potential of ERG. The 2nd annual meeting of the Israeli translational research network, ministry of innovation, science, and technology.
32. Berger T, Yahalom V, Giladi O, Kugler E, Shochat T, Meirman V, Gal E, Klebovsky T, Wolach O, Yeshurun M, Raanani P, Shargian L, Pasvolsky O. Effect of Premedication Prior to Platelet Transfusion on Platelet Increment Among Hemato-Oncological Patients. EHA Annual Meeting.